Analysts at Credit Suisse downgraded Pharmacyclics Inc. PCYC from Outperform to Neutral.
The price target for Pharmacyclics has been raised from $163.00 to $233.00.
Pharmacyclics shares have gained 57.09% over the past 52 weeks, while the S&P 500 index has surged 13.51% in the same period.
Pharmacyclics' shares declined 1.75% to $214.00 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in